PUNIT DHILLON - 26 Aug 2024 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Chief Executive Officer, Director
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
Issuer symbol
SKYE
Transactions as of
26 Aug 2024
Net transactions value
$0
Form type
4
Filing time
27 Aug 2024, 17:20:42 UTC
Previous filing
01 Mar 2024
Next filing
30 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SKYE Common Stock Other +15,727 +4% 412,733 26 Aug 2024 Direct F1
holding SKYE Common Stock 9,343 26 Aug 2024 Trust F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares received by reporting person in connection with one of Issuer's shareholders pro rata distribution of common stock of Issuer to its shareholders.
F2 Shares held by a family trust of which the reporting person is the trustee.